Skip to content

US · LBRX · BIOTECHNOLOGY

LB Pharmaceuticals Inc Common Stock (LBRX) intrinsic value and stock valuation

$38.85as of 2026-11-21 · Mkt cap 1.38B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

LB Pharmaceuticals Inc Common Stock DCF and intrinsic value

InvestorsCraft values LBRX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from LBRX’s statements →

LB Pharmaceuticals Inc Common Stock Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology New York, NY 10119 lbpharma.us

How the business is doing

Fiscal 2022–2025, USD

Revenue
$0.00
20222025
Net income
-$-25.2M
20222025
Free cash flow
-$-35.26M
20222025
Total equity
$301.3M
20222025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Operating income-$-30.4M-$-64.83M-$-11.38M-$-2.81M
Net income-$-25.2M-$-63.1M-$-6.28M-$-14.35M
EPSd-$-996.05K-$-17.82M-$-1.77M-$-4.05M
Operating cash flow-$-35.21M-$-53.05M-$-12.09M-$-2.73M
Capital expenditure-$-50K-$-770K-$-30K$0.00
Free cash flow-$-35.26M-$-53.82M-$-12.12M-$-2.73M
Total assets$312.9M$33.5M$45.7M$21.5M
Total debt$3.57M$3.7M$0.00$24.2M
Net debt-$-246.6M-$-19.27M-$-14.98M$2.74M
Total equity$301.3M-$-94.55M-$-34.47M-$-28.81M
Cash and short-term investments$295.2M$28M$43.3M$21.4M
Income statement
2025202420232022
Revenue$0.00$0.00$0.00$0.00
Cost of revenue$0.00$0.00$0.00$0.00
Gross profit$0.00$0.00$0.00$0.00
Research and development expenses$16.7M$51.2M$7.84M$1.35M
Selling, general and administrative expenses$13.7M$13.7M$3.53M$1.46M
Other expenses$0.00$0.00$0.00$0.00
Operating expenses$30.4M$64.8M$11.4M$2.81M
Cost and expenses$30.4M$64.8M$11.4M$2.81M
Interest income$3.92M$1.72M$810K$70K
Interest expense$0.00$0.00$4.83M$2.15M
Depreciation and amortization$320K$90K$0.00$0.00
Ebitda-$-24.88M-$-63.01M-$-1.45M-$-12.19M
Operating income-$-30.4M-$-64.83M-$-11.38M-$-2.81M
Total other income/expenses, net$5.2M$1.73M$5.1M-$-11.54M
Income before tax-$-25.2M-$-63.1M-$-6.27M-$-14.35M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-25.2M-$-63.1M-$-6.28M-$-14.35M
Weighted average shares outstanding$25.3M$3.54M$3.54M$3.54M
Weighted average diluted shares outstanding$25.3M$3.54M$3.54M$3.54M
Balance sheet
2025202420232022
Cash and short-term investments$295.2M$28M$43.3M$21.4M
Net receivables$0.00$0.00$0.00$0.00
Inventory$0.00$0.00$0.00$0.00
Total current assets$308.4M$28.9M$45.6M$21.5M
Property, plant and equipment, net$3.73M$4.16M$20K$0.00
Goodwill and intangible assets$0.00$0.00$0.00$0.00
Long-term investments$770K$0.00$0.00$0.00
Total non-current assets$4.5M$4.66M$20K$0.00
Total assets$312.9M$33.5M$45.7M$21.5M
Accounts payable$2.13M$2.32M$1.39M$160K
Short-term debt$730K$490K$0.00$0.00
Deferred revenue$0.00$0.00$0.00$0.00
Total current liabilities$7.44M$8.11M$2.61M$470K
Long-term debt$2.84M$3.22M$0.00$24.2M
Deferred revenue, non-current$0.00$0.00$0.00$0.00
Total non-current liabilities$4.18M$120M$77.5M$49.8M
Capital lease obligations$2.84M$3.7M$0.00$0.00
Total liabilities$11.6M$128.1M$80.1M$50.3M
Common stock$0.00$0.00$0.00$0.00
Retained earnings-$-129.53M-$-104.32M-$-41.22M-$-34.95M
Accumulated other comprehensive income (loss)$170K$110K$270K$0.00
Total equity$301.3M-$-94.55M-$-34.47M-$-28.81M
Total investments$45.8M$5.02M$28.3M$0.00
Total debt$3.57M$3.7M$0.00$24.2M
Net debt-$-246.6M-$-19.27M-$-14.98M$2.74M
Cash flow statement
2025202420232022
Net income-$-25.2M-$-63.1M-$-6.28M-$-14.35M
Depreciation and amortization$320K$90K$0.00$0.00
Stock-based compensation$0.00$3.16M$290K$430K
Change in working capital-$-13.65M$3.31M-$-1.31M$90K
Accounts receivable-$-270K$110K-$-150K$0.00
Inventory$0.00$0.00$0.00$0.00
Accounts payable-$-910K$0.00$0.00$0.00
Net cash provided by operating activities-$-35.21M-$-53.05M-$-12.09M-$-2.73M
Investments in property, plant and equipment-$-50K-$-770K-$-30K$0.00
Acquisitions, net$0.00$0.00$0.00$0.00
Net cash used for investing activities-$-39.89M$23.2M-$-28.01M$120K
Common stock issued$302.6M$0.00$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$302.6M$38.3M$33.7M$23M
Net change in cash$227.2M$8.5M-$-6.42M$20.4M
Cash at end of period$250.2M$23.5M$15M$21.4M
Operating cash flow-$-35.21M-$-53.05M-$-12.09M-$-2.73M
Capital expenditure-$-50K-$-770K-$-30K$0.00
Free cash flow-$-35.26M-$-53.82M-$-12.12M-$-2.73M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About LB Pharmaceuticals Inc Common Stock

        This biopharmaceutical firm is currently in the clinical development stage, concentrating on the creation of innovative treatments for neuropsychiatric disorders such as schizophrenia and bipolar depression. Central to their pipeline is LB-102, their primary investigational drug, which is a methylated variant of amisulpride.

        CEO
        Heather D. Turner
        Employees
        27
        Beta
        0.42

        Explore

        Frequently asked questions

        What is the intrinsic value of LB Pharmaceuticals Inc Common Stock (LBRX)?

        InvestorsCraft does not currently publish an intrinsic value for LBRX. How the IC value is calculated.

        Is LBRX undervalued?

        InvestorsCraft does not publish an undervaluation signal for LBRX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.